Results 81 to 90 of about 13,679 (137)

Manifestações Dermatológicas do Mieloma Múltiplo

, 2013
INTRODUÇÃO: O mieloma múltiplo (MM), também conhecido como Doença de Kahler, é uma neoplasia maligna de linfócitos B cujos clones se acumulam predominantemente na medula óssea, ocasionando destruição óssea substancial e produzindo proteínas monoclonais ...
Lima, Renata Silva
core  

Primary systemic amyloidosis, acquired cutis laxa and cutaneous mucinosis in a patient with multiple myeloma. [PDF]

An Bras Dermatol, 2013
Lavorato FG, Alves Mde F, Maceira JM, Unterstell N, Serpa LA, Azulay-Abulafia L.   +5 more
europepmc   +1 more source

Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis. [PDF]

Haematologica, 2023
Mangiacavalli S, Cartia CS, Galli M, Pezzatti S, Belotti A, Fazio F, Mina R, Marcatti M, Cafro A, Zambello R, Paris L, Barilà G, Olivares C, Pompa A, Mazza R, Farina F, Soldarini M, Benvenuti P, Pagani G, Palumbo M, Masoni V, Ferretti VV, Klersy C, Arcaini L, Petrucci MT.   +24 more
europepmc   +1 more source

Psychometric properties of the Chilean version of the quality of life questionnaire for multiple myeloma. [PDF]

Rev Bras Enferm
Lorca LA, Sacomori C, Peña C, Barrera C, Salazar M, Leão I, Valladares X, Rojas C.   +7 more
europepmc   +1 more source

Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience. [PDF]

Cancers (Basel), 2023
Mingrone G, Astarita A, Colomba A, Catarinella C, Cesareo M, Airale L, Paladino A, Leone D, Vallelonga F, Bringhen S, Gay F, Veglio F, Milan A.   +12 more
europepmc   +1 more source

Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy : Correction to: annals of hematology. [PDF]

Ann Hematol
Conticello C, Del Fabro V, Romano A, Mele A, Mina R, Bringhen S, Orofino A, Antonioli E, Pulini S, De Paoli L, Za T, Cotzia E, Elia F, Casson A, Prete E, Citiso S, Liberatore C, Margiotta-Casaluci G, Fazio F, Morè S, Attucci I, Accardi F, Bongarzoni V, Mangiacavalli S, Rossi E, Mannina D, Garibaldi B, Rizzi R, Di Cecca M, Rossini B, Uccello G, Botta C, Leotta D, Vincelli D, Gentile M, Piciocchi A, Marsili G, Patriarca F, Zambello R, Musto P, Boccadoro M, Offidani M, Petrucci MT, Di Raimondo F.   +43 more
europepmc   +1 more source

JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib. [PDF]

Br J Haematol
Ceccardi A, Dameri M, Ravera F, Gilardi N, Stabile M, Lombardo I, Ceresa D, Colombo M, Vigo T, Cigolini B, Rivoli G, Dragani M, Solimano I, Garuti A, Bellodi A, Ballestrero A, Ferrando L, Zoppoli G.   +17 more
europepmc   +1 more source

Correction: Colomba et al. Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. Cancers 2024, 16, 3081. [PDF]

Cancers (Basel)
Colomba A, Astarita A, Mingrone G, Airale L, Catarinella C, Vallelonga F, Leone D, Cesareo M, Paladino A, Bringhen S, Gay F, Pedrizzetti G, Veglio F, Milan A.   +13 more
europepmc   +1 more source

Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. [PDF]

Haematologica, 2022
De Stefano V, Larocca A, Carpenedo M, Cavo M, Di Raimondo F, Falanga A, Offidani M, Petrucci MT, Ruggeri M, Santi RM, Barosi G.   +10 more
europepmc   +1 more source